Poly (ADP-Ribose) polymerase inhibitors: Recent advances and future development

Journal of Clinical Oncology

Volumn 33, Issue 12, 2015, Pages 1397-1406

  Scott, Clare L ^a   Swisher, Elizabeth M ^b   Kaufmann, Scott H ^c  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF WASHINGTON   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; MICRORNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; RUCAPARIB; TEMOZOLOMIDE; VELIPARIB; ENZYME INHIBITOR;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CIRCULATING TUMOR CELL; CYTOTOXICITY; DNA DAMAGE; DNA END JOINING REPAIR; DRUG RESEARCH; ENZYME INHIBITION; GERMLINE MUTATION; GLIOBLASTOMA; HEMATOLOGIC DISEASE; HUMAN; LOW DRUG DOSE; ONCOLOGY; OVARY CARCINOMA; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR; SOMATIC MUTATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; ENZYMOLOGY; FEMALE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; ENZYME INHIBITORS; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS;

EID: 84929440309     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.8848     Document Type: Review

References (156)

1. Ashworth A: A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:3785-3790, 2008
2. Reinbolt RE, Hays JL: The role of PARP inhibitors in the treatment of gynecologic malignancies. Front Oncol 3:237, 2013
3. Lee JM, Ledermann JA, Kohn EC: PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 25:32-40, 2014
4. Tutt A, Robson M, Garber JE, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 376:235-244, 2010
5. Audeh MW, Carmichael J, Penson RT, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet 376:245-251, 2010
6. Ledermann J, Harter P, Gourley C, et al: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366:1382-1392, 2012
7. Ledermann J, Harter P, Gourley C, et al: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15:852-861, 2014
8. McCabe N, Turner NC, Lord CJ, et al: Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66:8109-8115, 2006
9. L'heureux S, Ledermann JA, Kaye SB, et al: Characterization of ovarian cancer long-term responders on olaparib. J Clin Oncol 32:359s, 2014 (suppl 15s; abstr 5534)
10. Ang JE, Gourley C, Powell CB, et al: Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: A multi-institutional study. Clin Cancer Res 19:5485-5493, 2013
11. Lee JM, Hays JL, Annunziata CM, et al: Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst 106:dju089, 2014
12. Liu JF, Barry WT, Birrer M, et al: Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 study. Lancet Oncol 15:1207-1214, 2014
13. Burgess M, Puhalla S: BRCA 1/2-mutation related and sporadic breast and ovarian cancers: More alike than different. Front Oncol 4:19, 2014
14. Swisher EM, McNeish IA, Coleman RL, et al: ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response. J Clin Oncol 32:380s, 2014 (suppl 15s; abstr TPS5619)
15. Lehmann BD, Bauer JA, Chen X, et al: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750-2767, 2011
16. Balko JM, Giltnane JM, Wang K, et al: Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 4:232-245, 2014
17. Gonzalez-Angulo AM, Timms KM, Liu S, et al: Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17:1082-1089, 2011
18. Shen Y, Rehman FL, Feng Y, et al: BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 19:5003-5015, 2013
19. O'Sullivan CC, Moon DH, Kohn EC, et al: Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors. Front Oncol 4:42, 2014
20. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al: Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: An open-label phase II study. J Clin Oncol 32:701s, 2014 (suppl 15s; abstr 11024)
21. Gelmon KA, Tischkowitz M, Mackay H, et al: Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12:852-861, 2011
22. Chambon P, Weill JD, Mandel P: Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 11:39-43, 1963
23. Sugimura T, Fujimura S, Hasegawa S, et al: Polymerization of the adenosine 5′-diphosphate ribose moiety of NAD by rat liver nuclear enzyme. Biochim Biochim Biophys Acta 138:438-441, 1967
24. Amé JC, Spenlehauer C, de Murcia G: The PARP superfamily. Bioessays 26:882-893, 2004
25. Hassa PO, Haenni SS, Elser M, et al: Nuclear ADP-ribosylation reactions in mammalian cells: Where are we today and where are we going? Microbiol Mol Biol Rev 70:789-829, 2006
26. Schreiber V, Dantzer F, Ame JC, et al: Poly-(ADP-ribose): Novel functions for an old molecule. Nat Rev Mol Cell Biol 7:517-528, 2006
27. Rouleau M, Patel A, Hendzel MJ, et al: PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10:293-301, 2010
28. Curtin NJ: DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 12:801-817, 2012
29. Satoh MS, Lindahl T: Role of poly (ADP-ribose) formation in DNA repair. Nature 356:356-358, 1992
30. Ahel I, Ahel D, Matsusaka T, et al: Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. Nature 451:81-85, 2008
31. Zhang F, Chen Y, Li M, et al: The oligonucleotide/oligosaccharide-binding fold motif is a poly(ADP-ribose)-binding domain that mediates DNA damage response. Proc Natl Acad Sci U S A 111:7278-7283, 2014
32. Bürkle A: Physiology and pathophysiology of poly(ADP-ribosyl)ation. Bioessays 23:795-806, 2001
33. Kim MY, Zhang T, Kraus WL: Poly(ADP-ribosyl)ation by PARP-1: "PAR-laying" NAD+ into a nuclear signal. Genes Dev 19:1951-1967, 2005
34. Hassa PO, Hottiger MO: The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci 13:3046-3082, 2008
35. Sousa FG, Matuo R, Soares DG, et al: PARPs and the DNA damage response. Carcinogenesis 33:1433-1440, 2012
36. De Vos M, Schreiber V, Dantzer F: The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art. Biochem Pharmacol 84:137-146, 2012
37. de Murcia G, Ménissier de Murcia J: Poly(ADP-ribose) polymerase: A molecular nick-sensor. Trends Biochem Sci 19:172-176, 1994
38. Langelier MF, Planck JL, Roy S, et al: Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science 336:728-732, 2012
39. Hassler M, Ladurner AG: Towards a structural understanding of PARP1 activation and related signalling ADP-ribosyl-transferases. Curr Opin Struct Biol 22:721-729, 2012
40. Langelier MF, Pascal JM: PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis. Curr Opin Struct Biol 23:134-143, 2013
41. Juarez-Salinas H, Sims JL, Jacobson MK: Poly(ADP-ribose) levels in carcinogen-treated cells. Nature 282:740-741, 1979
42. Mendoza-Alvarez H, Alvarez-Gonzalez R: Poly(ADP-ribose) polymerase is a catalytic dimer and the automodification reaction is intermolecular. J Biol Chem 268:22575-22580, 1993
43. Althaus FR, Richter C: ADP-ribosylation of proteins: Enzymology and biological significance. Mol Biol Biochem Biophys 37:1-237, 1987
44. Realini CA, Althaus FR: Histone shuttling by poly(ADP-ribosylation). J Biol Chem 267:18858-18865, 1992
45. Malanga M, Althaus FR: Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand break resealing. J Biol Chem 279:5244-5248, 2004
46. Gagné JP, Isabelle M, Lo KS, et al: Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. Nucleic Acids Res 36:6959-6976, 2008
47. Gagné JP, Pic E, Isabelle M, et al: Quantitative proteomics profiling of the poly(ADP-ribose)-related response to genotoxic stress. Nucleic Acids Res 40:7788-7805, 2012
48. Gibson BA, Kraus WL: New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 13:411-424, 2012
49. Haince JF, McDonald D, Rodrigue A, et al: PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J Biol Chem 283:1197-1208, 2008
50. Li M, Yu X: Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. Cancer Cell 23:693-704, 2013
51. Bonicalzi ME, Haince JF, Droit A, et al: Regulation of poly(ADP-ribose) metabolism by poly(ADP-ribose) glycohydrolase: Where and when? Cell Mol Life Sci 62:739-750, 2005
52. Meyer-Ficca ML, Meyer RG, Jacobson EL, et al: Poly(ADP-ribose) polymerases: Managing genome stability. Int J Biochem Cell Biol 37:920-926, 2005
53. Min W, Wang ZQ: Poly (ADP-ribose) glycohydrolase (PARG) and its therapeutic potential. Front Biosci (Landmark Ed) 14:1619-1626, 2009
54. de Murcia JM, Niedergang C, Trucco C, et al: Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A 94:7303-7307, 1997
55. Masson M, Niedergang C, Schreiber V, et al: XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 18:3563-3571, 1998
56. Trucco C, Oliver FJ, de Murcia G, et al: DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines. Nucleic Acids Res 26:2644-2649, 1998
57. Horton JK, Watson M, Stefanick DF, et al: XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res 18:48-63, 2008
58. Schultz N, Lopez E, Saleh-Gohari N, et al: Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res 31:4959-4964, 2003
59. Helleday T, Bryant HE, Schultz N: Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 4:1176-1178, 2005
60. Haince JF, Kozlov S, Dawson VL, et al: Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. J Biol Chem 282:16441-16453, 2007
61. Ciccia A, Elledge SJ: The DNA damage response: Making it safe to play with knives. Mol Cell 40:179-204, 2010
62. Roy R, Chun J, Powell SN: BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat Rev Cancer 12:68-78, 2012
63. Hu Y, Petit SA, Ficarro SB, et al: PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair. Cancer Discov 4:1430-1447, 2014
64. Wang M, Wu W, Wu W, et al: PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res 34:6170-6182, 2006
65. Robert I, Dantzer F, Reina-San-Martin B: Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination. J Exp Med 206:1047-1056, 2009
66. Soni A, Siemann M, Grabos M, et al: Requirement for Parp-1 and DNA ligases 1 or 3 but not of Xrcc1 in chromosomal translocation formation by backup end joining. Nucleic Acids Res 42:6380-6392, 2014
67. Yang YG, Cortes U, Patnaik S, et al: Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks. Oncogene 23:3872-3882, 2004
68. Bryant HE, Petermann E, Schultz N, et al: PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J 28:2601-2615, 2009
69. Ying S, Hamdy FC, Helleday T: Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1. Cancer Res 72:2814-2821, 2012
70. Min W, Bruhn C, Grigaravicius P, et al: Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation. Nat Commun 4:2993, 2013
71. Krishnakumar R, Kraus WL: The PARP side of the nucleus: Molecular actions, physiological outcomes, and clinical targets. Mol Cell 39:8-24, 2010
72. de Murcia G, Huletsky A, Poirier GG: Modulation of chromatin structure by poly(ADP-ribosyl)ation. Biochem Cell Biol 66:626-635, 1988
73. Quénet D, El Ramy R, Schreiber V, et al: The role of poly(ADP-ribosyl)ation in epigenetic events. Int J Biochem Cell Biol 41:60-65, 2009
74. Leung AK, Vyas S, Rood JE, et al: Poly(ADP-ribose) regulates stress responses and microRNA activity in the cytoplasm. Mol Cell 42:489-499, 2011
75. Bai P, Cantó C: The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab 16:290-295, 2012
76. Luo X, Kraus WL: On PAR with PARP: Cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev 26:417-432, 2012
77. Wang ZQ, Auer B, Stingl L, et al: Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev 9:509-520, 1995
78. Durkacz BW, Omidiji O, Gray DA, et al: (ADP-ribose)n participates in DNA excision repair. Nature 283:593-596, 1980
79. Chatterjee S, Berger SJ, Berger NA: Poly(ADP-ribose) polymerase: A guardian of the genome that facilitates DNA repair by protecting against DNA recombination. Mol Cell Biochem 193:23-30, 1999
80. Amé JC, Rolli V, Schreiber V, et al: PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase J Biol Chem 274:17860-17868, 1999
81. Schreiber V, Amé JC, Dollé P, et al: Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 277:23028-23036, 2002
82. Rulten SL, Fisher AE, Robert I, et al: PARP-3 and APLF function together to accelerate nonhomologous end-joining. Mol Cell 41:33-45, 2011
83. Boehler C, Gauthier LR, Mortusewicz O, et al: Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. Proc Natl Acad Sci U S A 108:2783-2788, 2011
84. Wahlberg E, Karlberg T, Kouznetsova E, et al: Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 30:283-288, 2012
85. Bryant HE, Schultz N, Thomas HD, et al: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917, 2005
86. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921, 2005
87. Lord CJ, McDonald S, Swift S, et al: A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) 7:2010-2019, 2008
88. Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al: PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2:53ra75, 2010
89. Dantzer F, Schreiber V, Niedergang C, et al: Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie 81:69-75, 1999
90. Iglehart JD, Silver DP: Synthetic lethality: A new direction in cancer-drug development. N Engl J Med 361:189-191, 2009
91. Yap TA, Sandhu SK, Carden CP, et al: Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 61:31-49, 2011
92. Gottipati P, Vischioni B, Schultz N, et al: Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 70:5389-5398, 2010
93. Patel A, Sarkaria J, Kaufmann SH: Nonhomologous end-joining drives PARP inhibitor synthetic lethality in homologous recombination-deficient cells. Proc Natl Acad Sci USA108:3406-3411, 2011
94. Benjamin RC, Gill DM: Poly(ADP-ribose) synthesis in vitro programmed by damaged DNA: A comparison of DNA molecules containing different types of strand breaks. J Biol Chem 255:10502-10508, 1980
95. Küpper JH, deMurcia G, Bürkle A: Inhibition of poly(ADP-ribosyl)ation by overexpressing the poly(ADP-ribose) polymerase DNA-binding domain in mammalian cells. J Biol Chem 265:18721-18724, 1990
96. Molinete M, Vermeulen W, Bürkle A, et al: Overproduction of the poly(ADP-ribose) polymerase DNA-binding domain blocks alkylation-induced DNA repair synthesis in mammalian cells. EMBO J 12:2109-2117, 1993
97. Liu X, Han EK, Anderson M, et al: Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. Mol Cancer Res 7:1686-1692, 2009
98. Murai J, Zhang Y, Morris J, et al: Rationale for PARP inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther 349:408-416, 2014
99. Patel AG, Flatten KS, Schneider PA, et al: Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase inhibitors reflects poisoning of both enzymes. J Biol Chem 287:4198-4210, 2012
100. Murai J, Huang SY, Das BB, et al: Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72:5588-5599, 2012
101. Bonner WM, Redon CE, Dickey JS, et al: GammaH2AX and cancer. Nat Rev Cancer 8:957-967, 2008
102. De Lorenzo SB, Patel AG, Hurley RM, et al: The elephant and the blind men: Making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol 3:228, 2013
103. Lieber MR: The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem 79:181-211, 2010
104. Hochegger H, Dejsuphong D, Fukushima T, et al: Parp-1 protects homologous recombination from interference by Ku and ligase IV in vertebrate cells. EMBO J 25:1305-1314, 2006
105. Paddock MN, Bauman AT, Higdon R, et al: Competition between PARP-1 and Ku70 control the decision between high-fidelity and mutagenic DNA repair. DNA Repair (Amst) 10:338-343, 2011
106. Murai J, Yang K, Dejsuphong D, et al: The USP1/UAF1 complex promotes double-strand break repair through homologous recombination. Mol Cell Biol 31:2462-2469, 2011
107. Williamson CT, Kubota E, Hamill JD, et al: Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol Med 4:515-527, 2012
108. Ceccaldi R, Liu JC, Amunugama R, et al: Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature 518:258-262, 2015
109. Bunting SF, Callén E, Wong N, et al: 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141:243-254, 2010
110. Jaspers JE, Kersbergen A, Boon U, et al: Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 3:68-81, 2013
111. Wang J, Aroumougame A, Lobrich M, et al: PTIP associates with Artemis to dictate DNA repair pathway choice. Genes Dev 28:2693-2698, 2014
112. Fong PC, Yap TA, Boss DS, et al: Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28:2512-2519, 2010
113. Sandhu SK, Schelman WR, Wilding G, et al: The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: A phase 1 dose-escalation trial. Lancet Oncol 14:882-892, 2013
114. Kaye SB, Lubinski J, Matulonis U, et al: Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30:372-379, 2012
115. Edwards SL, Brough R, Lord CJ, et al: Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451:1111-1115, 2008
116. Sakai W, Swisher EM, Karlan BY, et al: Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451:1116-1120, 2008
117. Swisher EM, Sakai W, Karlan BY, et al: Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68:2581-2586, 2008
118. Norquist B, Wurz KA, Pennil CC, et al: Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 29:3008-3025, 2011
119. Barber LJ, Sandhu S, Chen L, et al: Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol 229:422-429, 2013
120. Johnson N, Johnson SF, Yao W, et al: Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci U S A 110:17041-17046, 2013
121. Bouwman P, Aly A, Escandell JM, et al: 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 17:688-695, 2010
122. Pennington KP, Walsh T, Harrell MI, et al: Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 20:764-775, 2014
123. Forster MD, Dedes KJ, Sandhu S, et al: Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol 8:302-306, 2011
124. Bang YJ, Im SA, Lee KW, et al: Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: A randomized, double-blind phase II study. J Clin Oncol 31:246s, 2013 (suppl 15s; abstr 4013)
125. Baldwin RL, Nemeth E, Tran H, et al: BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study. Cancer Res 60:5329-5333, 2000
126. Esteller M, Silva JM, Dominguez G, et al: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92:564-569, 2000
127. Swisher EM, Gonzalez RM, Taniguchi T, et al: Methylation and protein expression of DNA repair genes: Association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer 8:48, 2009
128. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615, 2011
129. Nowsheen S, Cooper T, Stanley JA, et al: Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. PLoS One 7:e46614, 2012
130. Johnson N, Li YC, Walton ZE, et al: Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 17:875-882, 2011
131. Juvekar A, Burga LN, Hu H, et al: Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2:1048-1063, 2012
132. Ibrahim YH, García-García C, Serra V, et al: PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2:1036-1047, 2012
133. Huntoon CJ, Flatten KS, Wahner Hendrickson AE, et al: ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res 73:3683-3691, 2013
134. Hegan DC, Lu Y, Stachelek GC, et al: Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci U S A 107:2201-2206, 2010
135. Huehls AM, Wagner JM, Huntoon CJ, et al: Poly(ADP-ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells. Cancer Res 71:4944-4954, 2011
136. Geng L, Huehls AM, Wagner JM, et al: Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil. PLoS One 6:e28862, 2011
137. Zong WX, Ditsworth D, Bauer DE, et al: Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 18:1272-1282, 2004
138. Hussain M, Carducci MA, Slovin S, et al: Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer. Invest New Drugs 32:904-912, 2014
139. Kummar S, Chen A, Ji J, et al: Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 71:5626-5634, 2011
140. Mendeleyev J, Kirsten E, Hakam A, et al: Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide: Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. Biochem Pharmacol 50:705-714, 1995
141. O'Shaughnessy J, Schwartzberg LA, Danso MA, et al: A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 29:81s, 2011 (suppl; abstr 1007)
142. Domchek SM, Mitchell G, Lindeman GJ, et al: Challenges to the development of new agents for molecularly defined patient subsets: Lessons from BRCA1/2-associated breast cancer. J Clin Oncol 29:4224-4226, 2011
143. Liu X, Shi Y, Maag DX, et al: Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 18:510-523, 2012
144. Patel AG, De Lorenzo SB, Flatten KS, et al: Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro. Clin Cancer Res 18:1655-1662, 2012
145. Abkevich V, Timms KM, Hennessy BT, et al: Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 107:1776-1782, 2012
146. Birkbak NJ, Wang ZC, Kim JY, et al: Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2:366-375, 2012
147. Popova T, Manié E, Rieunier G, et al: Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 72:5454-5462, 2012
148. Wang ZC, Birkbak NJ, Culhane AC, et al: Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 18:5806-5815, 2012
149. Watkins JA, Irshad S, Grigoriadis A, et al: Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res 16:211, 2014
150. Haluska P, Timms KM, AlHilli M, et al: Homologous recombination deficiency score and niraparib efficacy in high grade ovarian cancer. Presented at the 26th European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium, Barcelona, Spain, November 18-21, 2014
151. Swisher E, Brenton J, Kaufmann S, et al: Updated clinical and preliminary correlative results of Ariel2, a phase 2 study to identify ovarian cancer patients likely to respond to rucaparib. Presented at the 26th European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium, Barcelona, Spain, November 18-21, 2014
152. Kummar S, Ji J, Morgan R, et al: A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 18:1726-1734, 2012
153. Moore KN, DiSilvestro P, Lowe ES, et al: SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm). J Clin Oncol 32:379s, 2014 (suppl 15s; abstr TPS5616)
154. Lord CJ, Ashworth A: Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 19:1381-1388, 2013
155. Bouwman P, Jonkers J: Molecular pathways: How can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res 20:540-547, 2014
156. To C, Kim EH, Royce DB, et al: The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev Res (Phila) 7:698-707, 2014